Overview of the mucopolysaccharidoses

Rheumatology

Volumn 50, Issue SUPPL. 5, 2011, Pages

  Muenzer, Joseph ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Enzyme replacement therapy; Genetic disorder; Glycosaminoglycan; Haematopoietic stem cell transplantation.; Mucopolysaccharidoses

Indexed keywords

ANTIHISTAMINIC AGENT; RECOMBINANT ENZYME; STEROID;

ANAPHYLAXIS; ARTICLE; CLINICAL FEATURE; DISEASE SEVERITY; ENZYME DEFICIENCY; ENZYME REPLACEMENT; FEVER; FLUSHING; GENE MUTATION; GENETIC DISORDER; HEADACHE; HEART ARRHYTHMIA; HEART FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUNTER SYNDROME; HURLER SYNDROME; HYPERSENSITIVITY REACTION; LARYNX EDEMA; MAROTEAUX LAMY SYNDROME; MORBIDITY; MORTALITY; MUCOPOLYSACCHARIDOSIS TYPE 7; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RHEUMATOLOGY; SCHEIE SYNDROME; SIDE EFFECT; TONGUE EDEMA; URTICARIA;

DISEASE PROGRESSION; EARLY DIAGNOSIS; ENZYME REPLACEMENT THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MUCOPOLYSACCHARIDOSES; MUSCULOSKELETAL DISEASES;

EID: 84855577104     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker394     Document Type: Article

References (71)

1. Neufeld EU, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, ed. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw-Hill, 2001; 3421-52.
2. Tomatsu S, Okamura K, Maeda H et al. Keratan sulphate levels in mucopolysaccharidoses and mucolipidoses. J Inherit Metab Dis 2005; 28:187-202.
3. Tomatsu S, Gutierrez MA, Ishimaru T et al. Heparan sulfate levels in mucopolysaccharidoses and mucolipidoses. J Inherit Metab Dis 2005; 28:743-57.
4. Federico A, Capece G, Cecio A et al. Sanfilippo B syndrome (MPS III B): case report with analysis of CSF mucopolysaccharides and conjunctival biopsy. J Neurol 1981; 225:77-83.
5. Munoz-Rojas MV, Vieira T, Costa R et al. Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression. Am J Med Genet A 2008; 146A:2538-44.
6. Tuschl K, Gal A, Paschke E et al. Mucopolysaccharidosis type II in females: case report and review of literature. Pediatr Neurol 2005; 32:270-2.
7. Sukegawa K, Matsuzaki T, Fukuda S et al. Brother/sister siblings affected with Hunter disease: evidence for skewed X chromosome inactivation. Clin Genet 1998; 53:96-101.
8. Cudry S, Tigaud I, Froissart R et al. MPS II in females: molecular basis of two different cases. J Med Genet 2000; 37:E29.
9. Peters C. Hematopoietic cell transplantation for storage diseases. In: Blume KG, Forman SJ, Appelbaum FR, eds. Hematopoietic Stem Cell Transplantation. Malden, MA: Blackwell Science, 2004:1455-70.
10. McGill JJ, Inwood AC, Coman DJ et al. Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age-a sibling control study. Clin Genet 2010; 77:492-8.
11. Schulze-Frenking G, Jones SA, Roberts J et al. Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II. J Inherit Metab Dis 2011; 34:203-8.
12. Vijay S, Wraith JE. Clinical presentation and follow-up of patients with the attenuated phenotype of mucopolysaccharidosis type I. Acta Paediatr 2005; 94:872-7.
13. Chamoles NA, Blanco M, Gaggioli D. Diagnosis of alpha-L-iduronidase deficiency in dried blood spots on filter paper: the possibility of newborn diagnosis. Clin Chem 2001; 47:780-1.
14. Gelb MH, Turecek F, Scott CR et al. Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders. J Inherit Metab Dis 2006; 29: 397-404.
15. Meikle PJ, Grasby DJ, Dean CJ et al. Newborn screening for lysosomal storage disorders. Mol Genet Metab 2006; 88:307-14.
16. Baehner F, Schmiedeskamp C, Krummenauer F et al. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J Inherit Metab Dis 2005; 28:1011-7.
17. Poorthuis BJ, Wevers RA, Kleijer WJ et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet 1999; 105:151-6.
18. Meikle PJ, Hopwood JJ, Clague AE et al. Prevalence of lysosomal storage disorders. JAMA 1999; 281:249-54.
19. Nelson J. Incidence of the mucopolysaccharidoses in Northern Ireland. Hum Genet 1997; 101:355-8.
20. Nelson J, Crowhurst J, Carey B et al. Incidence of the mucopolysaccharidoses in Western Australia. Am J Med Genet 2003; 123:310-3.
21. Lowry RB, Renwick DH. Relative frequency of the Hurler and Hunter syndromes. N Engl J Med 1971; 284:221-2.
22. Applegarth DA, Toone JR, Lowry RB. Incidence of inborn errors of metabolism in British Columbia, 1969-1996. Pediatrics 2000; 105:e10.
23. Triggs-Raine B, Salo TJ, Zhang H et al. Mutations in HYAL1, a member of a tandemly distributed multigene family encoding disparate hyaluronidase activities, cause a newly described lysosomal disorder, mucopolysaccharidosis IX. Proc Natl Acad Sci USA 1999; 96: 6296-630.
24. Imundo L, Leduc CA, Guha S et al. A complete deficiency of hyaluronoglucosaminidase 1 (HYAL1) presenting as familial juvenile idiopathic arthritis. J Inherit Metab Dis 2011; 34:1013-22.
25. Bach G, Friedman R, Weissmann B et al. The defect in the Hurler and Scheie syndromes: deficiency of α-L-iduronidase. Proc Natl Acad Sci USA 1972; 69: 2048-51.
26. Muenzer J, Wraith JE, Clarke LA et al. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics 2009; 123:19-29.
27. Martin R, Beck M, Eng C et al. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics 2008; 121:e377-86.
28. Taybi H, Lachman RS. Radiology of Syndromes, Metabolic Disorders, and Skeletal Dysplasias. Mosby. 4th edn. New York: Mosby-Year Book, 1996:670-81.
29. Ashworth JL, Biswas S, Wraith E et al. Mucopolysaccharidoses and the eye. Surv Ophthalmol 2006; 51:1-17.
30. Bredenkamp JK, Smith ME, Dudley JP et al. Otolaryngologic manifestations of the mucopolysaccharidoses. Ann Otol Rhinol Layngol 1992; 101:472-8.
31. Muhlebach MS, Wooten W, Muenzer J. Respiratory manifestations in mucopolysaccharidoses. Paediatr Respir Rev 2010; 12:133-38.
32. Farina V, Leva F, Caso P et al. Echo-Doppler abnormalities in mucopolysaccharide storage diseases. Acta Paediatr 1992; 81:702-4.
33. Rigante D, Segni G. Cardiac structural involvement in mucopolysaccharidoses. Cardiology 2002; 98:18-20.
34. Haddad FS, Jones DHA, Vellodi A et al. Carpal tunnel syndrome in the mucopolysaccharidoses. J Bone Joint Surg 1997; 79-B:576-82.
35. Thappa DM, Singh A, Jaisankar TJ et al. Pebbling of the skin: a marker of Hunter's syndrome. Pediatr Dermatol 1998; 15:370-3.
36. Wraith JE. The mucopolysaccharidoses: a clinical review and guide to management. Arch Dis Child 1995; 72:263-7.
37. Barone R, Nigro F, Triulzi F et al. Clinical and neuroradiological follow-up in mucopolysaccharidosis type III (Sanfilippo syndrome). Neuropediatrics 1999; 30: 270-4.
38. Valstar MJ, Neijs S, Bruggenwirth HT et al. Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations. Ann Neurol 2010; 68: 876-87.
39. Northover H, Cowie RA, Wraith JE. Mucopolysaccharidosis type IVA (Morquio syndrome): a clinical review. J Inherit Metab Dis 1996; 19:357-65.
40. Valayannopoulos V, Nicely H, Harmatz P et al. Mucopolysaccharidosis VI. Orphanet J Rare Dis 2010; 5:5.
41. Swiedler SJ, Beck M, Bajbouj M et al. Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am J Med Genet 2005; 134A:144-50.
42. Hopwood JJ, Muller V. Biochemical discrimination of Hurler and Scheie syndromes. Clin Sci 1979; 57: 265-72.
43. Terlato NJ, Cox GF. Can mucopolysaccharidosis type I disease severity be predicted based on a patient's genotype? A comprehensive review of the literature. Genet Med 2003; 5:286-94.
44. Scott H, Bunge S, Gal A et al. Molecular genetics of mucopolysaccharidosis type I: diagnostic, clinical, and biological implications. Hum Mutat 1995; 6:288-302.
45. Froissart R, Moreira., da Silva I, Guffon N et al. Mucopolysaccharidosis type II: genotype/phenotype aspects. Acta Paediatr Suppl 2002; 91:82-7.
46. Tomatsu S, Fukuda S, Sukegawa K et al. Mucopolysaccharidosis type VII: characterization of mutations and molecular heterogeneity. Am J Hum Genet 1991; 48:89-96.
47. Mahalingam K, Janani S, Priya S et al. Diagnosis of mucopolysaccharidoses: how to avoid false positives and false negatives. Indian J Pediatr 2004; 71:29-32.
48. Hall CW, Liebaers I, Di Natale P et al. Enzymatic diagnosis of the genetic mucopolysaccharide storage disorders. Methods Enzymol 1978; 50:439-56.
49. Young EP. Prenatal diagnosis of Hurler disease by analysis of alpha-iduronidase in chorionic villi. J Inherit Metab Dis 1992; 15:224-30.
50. Filocamo M, Morrone A. Lysosomal storage disorders: molecular basis and laboratory testing. Hum Genomics 2011; 5:156-69.
51. Arn P, Wraith JE, Underhill L. Characterization of surgical procedures in patients with mucopolysaccharidosis type I: findings from the MPS I Registry. J Pediatr 2009; 154: 859-64.
52. Mendelsohn NJ, Harmatz P, Bodamer O et al. Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): data from the Hunter Outcome Survey. Genet Med 2010; 12:816-22.
53. Muhlebach MS, Wooten W, Muenzer J. Respiratory manifestations in mucopolysaccharidoses. Paediatr Respir Rev 2010; 12:133-8.
54. Hobbs JR, Hugh-Jones K, Barrett AJ et al. Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet 1981; 2:709-12.
55. Souillet G, Guffon N, Maire I et al. Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant 2003; 31:1105-17.
56. Herskhovitz E, Young E, Rainer J et al. Bone marrow transplantation for Maroteaux-Lamy syndrome (MPS VI): long-term follow-up. J Inherit Metab Dis 1999; 22:50-62.
57. Yamada Y, Kato K, Sukegawa K. Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619V mutation. Bone Marrow Transplant 1998; 21:629-34.
58. Braunlin EA, Stauffer NR, Peters CH et al. Usefulness of bone marrow transplantation in the Hurler syndrome. Am J Cardiol 2003; 92:882-6.
59. Weisstein JS, Delgado E, Steinbach LS et al. Musculoskeletal manifestations of Hurler syndrome: long-term follow-up after bone marrow transplantation. J Pediatr Orthop 2004; 24: 97-101.
60. Peters C, Krivit W. Hematopoietic cell transplantation for mucopolysaccharidosis IIB (Hunter syndrome). Bone Marrow Transplant 2000; 25:1097-9.
61. Sivakumur P, Wraith JE. Bone marrow transplantation in mucopolysaccharidosis type IIIA: a comparison of an early treated patient with his untreated sibling. J Inherit Metab Dis 1999; 22:849-50.
62. Prasad VK, Kurtzberg J. Transplant outcomes in mucopolysaccharidoses. Semin Hematol 2010; 47:59-69.
63. Boelens JJ, Wynn RF, O'Meara A et al. Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant 2007; 40:225-33.
64. Rovelli AM. The controversial and changing role of haematopoietic cell transplantation for lysosomal storage disorders: an update. Bone Marrow Transplant 2008; 41: S87-9.
65. Wraith JE, Beck M, Lane R et al. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics 2007; 120:e37-46.
66. Clarke LA, Wraith JE, Beck M et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 2009; 123:229-40.
67. Muenzer J, Wraith JE, Beck M et al. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome) [published correction appears in Genet Med 2006; 8:599]. Genet Med 2006; 8:465-73.
68. Harmatz P, Giugliani R, Schwartz I et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr 2006; 148:533-9.
69. Muenzer J, Beck M, Eng CM et al. Long-term, openlabeled extension study of idursulfase in the treatment of Hunter syndrome. Genet Med 2011; 13:95-101.
70. Muenzer J, Beck M, Giugliani R et al. Idursulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey. Genet Med 2011; 13:102-109.
71. Burton BK, Whiteman DA. On behalf of the HOS Investigators. Incidence and timing of infusion-related reactions in patients with mucopolysaccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS). Mol Genet Metab 2011; 103: 113-20.